MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

76.39
+3.49
+4.79%
After Hours: 76.00 -0.39 -0.51% 19:10 07/15 EDT
OPEN
75.10
PREV CLOSE
72.90
HIGH
77.22
LOW
73.65
VOLUME
842.33K
TURNOVER
--
52 WEEK HIGH
78.75
52 WEEK LOW
26.56
MARKET CAP
4.47B
P/E (TTM)
-6.0513
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BHVN stock price target is 85.00 with a high estimate of 109.00 and a low estimate of 60.00.

EPS

BHVN News

More
Morgan Stanley Maintains Equal-Weight on Biohaven Pharmaceutical, Raises Price Target to $60
Morgan Stanley maintains Biohaven Pharmaceutical (NYSE:BHVN) with a Equal-Weight and raises the price target from $50 to $60.
Benzinga · 9h ago
Khloe Kardashian Adds Biohaven Migraine Drug to Brand Touts
(Bloomberg) -- Khloe Kardashian is adding another role to her already busy schedule, migraine ambassador.The social influencer, who has been criticized for past associations with weight loss teas and smoothies has joined forces with Biohaven Pharmaceutical Hol
Bloomberg · 9h ago
After Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine
Khloé Kardashian joins efforts with Biohaven Pharmaceuticals to launch the Take Back Today campaign to empower people with migraine to share their stories in an online community, learn about new ways to manage their disease and get back to what matters most –
PR Newswire · 12h ago
ClearBridge Small Cap Growth Strategy Portfolio Manager Commentary Q2 2020
Seeking Alpha - Article · 4d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 6d ago
Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients
GlobeNewswire · 07/08 12:30
Insider Weekends: Harold Hamm Buys More Of Continental Resources
Seeking Alpha - Article · 06/29 06:03
Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/28 06:23

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About BHVN

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
More

Webull offers kinds of Biohaven Pharmaceutical Holding Co Ltd stock information, including NYSE:BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.